Clinical and cost outcomes following genomics-informed treatment for advanced cancers

Deirdre Weymann1 | Samantha Pollard1,2 | Brandon Chan1 | Emma Titmuss3 | Alexandra Bohm3 | Janessa Laskin4,5 | Steven J. M. Jones3,6 | Erin Pleasance3 | Jessica Nelson3 | Alexandra Fok3 | Howard Lim4,5 | Aly Karsan4,3,7 | Daniel J. Renouf4,5 | Kasmintan A. Schrader6,8,9 | Sophie Sun4,5 | Stephen Yip7,10 | David F. Schaeffer11 | Marco A. Marra3,6 | Dean A. Regier1,2

1Cancer Control Research, BC Cancer, Vancouver, Canada
2School of Population and Public Health, University of British Columbia, Vancouver, Canada
3Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada
4Division of Medical Oncology, BC Cancer, Vancouver, Canada
5Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada
6Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, Canada
7Department of Pathology & Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada
8Department of Molecular Oncology, BC Cancer, Vancouver, Canada
9Hereditary Cancer Program, BC Cancer, Vancouver, Canada
10Department of Pathology, BC Cancer, Vancouver, Canada
11Division of Anatomical Pathology, Vancouver General Hospital, University of British Columbia, Vancouver, Canada

Correspondence:
Dean A. Regier, BC Cancer Research Centre, 675 West 10th Avenue, Vancouver, BC, Canada.
Email: dregier@bccrc.ca

Funding information
This work was supported by the BC Personalized OncoGenomics Program; the BC Cancer Foundation Strategic Priorities Fund Awards; and Genome British Columbia/Genome Canada [G05CHS]. Marco A. Marra and Steven Jones are funded by the Canada Research Chairs Program

Abstract

Background: Single-arm trials are common in precision oncology. Owing to the lack of randomized counterfactual, resultant data are not amenable to comparative outcomes analyses. Difference-in-difference (DID) methods present an opportunity to generate causal estimates of time-varying treatment outcomes. Using DID, our study estimates within-cohort effects of genomics-informed treatment versus standard care on clinical and cost outcomes.

Methods: We focus on adults with advanced cancers enrolled in the single-arm BC Cancer Personalized OncoGenomics program between 2012 and 2017. All individuals had a minimum of 1-year follow up. Logistic regression explored baseline differences across patients who received a genomics-informed treatment versus a standard care treatment after genomic sequencing. DID estimated the incremental effects of genomics-informed treatment on time to treatment discontinuation (TTD), time to next treatment (TTNT), and costs. TTD and TTNT correlate with improved response and survival.
1 | INTRODUCTION

Precision oncology aligns interventions to individual molecular alterations and candidate pathways through rapidly characterizing interpatient genomic heterogeneity. Despite potential for individual health benefit, comprehensive genomic sequencing is infrequently reimbursed by healthcare systems.\(^1\) Limited adoption reflects a lack of evidence on the comparative benefits of comprehensive sequencing in a tumor-agnostic setting.\(^2\)

Few randomized controlled trials (RCTs) have examined precision oncology’s efficacy.\(^3\) SHIVA is the only completed RCT to evaluate comparative effects of using a tumor-agnostic multi-gene panel to inform targeted therapy versus conventionally selecting therapy.\(^4\) SHIVA failed to detect significant health benefits, partly reflecting insufficient sample sizes for subgroup analyses, a persistent challenge when assigning therapies according to genomic-level differences that make each cancer individually rare.\(^5\) Recognizing this as a barrier for RCTs, precision oncology frequently pursues single-arm trials.\(^6\)

To identify a comparator for single-arm trials that helps establish causality of effect and addresses selection bias, researchers are applying matching methods.\(^7,8\) Matching requires population-based data that may be unavailable or incomplete in some jurisdictions. Difference-in-difference (DID) analysis solely requires within-cohort data. By evaluating pre- and post-sequencing outcomes, DID is able to estimate net incremental effects adjusted for baseline differences across groups, as well as aggregate factors causing changes over time. Resulting effect estimates are causal, provided that patient outcomes have followed parallel trends across groups over time.\(^9\)

In this study, we use DID for evaluating single-arm precision oncology data.\(^10\) We estimate the within-cohort effects of genomics-informed treatment versus standard care among patients enrolled in British Columbia’s (BC) single-arm Personalized OncoGenomics (POG) program.\(^10,11\) Primary outcomes include time to treatment discontinuation (TTD), time to next treatment (TTNT), and treatment costs. TTD and TTNT are intermediate clinical endpoints strongly correlated with patient response and survival outcomes.\(^12–14\) Evaluations of these measures are common in advanced cancers, where treatment often continues beyond objective disease progression.\(^15–17\) Our null hypothesis is that there are no differences in TTD, TTNT, or treatment costs across patients receiving genomics-informed versus standard care. Our alternative hypothesis is that patients are treated with genomics-informed therapies longer than standard care therapies, reflected by longer TTD and TTNT, and that these therapies are more expensive than standard care.

2 | METHODS

Our retrospective cohort study uses data previously gathered in the BC Cancer POG program (NCT02155621), a single-group research study in British Columbia, Canada.\(^10,11\) POG uses whole-genome and transcriptome analysis (WGTA) to characterize and interpret genomic landscapes in an interdisciplinary setting. WGTA information was considered clinically actionable if a target or risk factor was found with the potential to affect the patient’s treatment plan or if the results yielded additional information beyond what was already known from prior genetic tests.\(^10\) A multidisciplinary tumor board reviewed WGTA results and prioritized clinically actionable alterations and corresponding treatment options. Patients who received at least one of the treatments listed as possible WGTA-informed actions by the tumor board were
considered to be on a genomics-informed treatment plan. Standard of care at BC Cancer instead involves using a combination of single-gene tests, multi-gene panels, and clinical practice guidelines to select treatment protocols for patients, including cytotoxic chemotherapies and targeted therapies that are either publicly reimbursed or accessed through BC Cancer’s Compassionate Access Program. Owing to non-randomized enrollment and variable treatment assignment, effects of WGTA-informed treatment on clinical outcomes and healthcare costs are poorly established.

2.1 Study population

Our study cohort was identified from adults who provided informed consent, enrolled in POG between July 2012 and August 2017, and received WGTA, as previously described.11 Eligible patients underwent biopsy, provided samples with sufficient tumor content to support reliable sequencing, and had high-quality sequence data generated. At enrollment, POG inclusion criteria were as follows: (i) locally advanced or metastatic disease considered incurable by the oncologist; and (ii) good performance status. Participants who progressed to advanced-stage disease years after their initial cancer diagnosis were eligible to participate in POG. Follow-up data were available until the end of 2018, with all included individuals having a minimum of 1-year follow up after WGTA.

The study design and methodology are presented in Figure 1. DID requires repeated outcomes data measured across treatment groups for a minimum of two study periods. We, therefore, divided our observed time horizon, from initial cancer diagnosis until 2018, into two study periods and measured outcomes for systemic therapy treatments initiated prior to sequencing (period 1) and post-sequencing (period 2). In period 1, all patients received a standard care treatment. After discontinuing this treatment, patients then began a new treatment in period 2. Treatment groups comprised: (1) patients whose first treatment in period 2 was classified as genomics informed by POG’s interdisciplinary tumor board; and (2) patients who instead received a standard care treatment not guided by their WGTA results in period 2.

We excluded patients who did not initiate a new line of systemic therapy in periods 1 (n = 40, 7%) and 2 (n = 184, 32%), as corresponding data were not amenable to DID. Excluded patients may have been treated with radiation therapy or surgical resection rather than systemic therapy prior to or following sequencing, for which TTD and TTNT are not evaluable. Following WGTA results, excluded patients were either pending further treatment or experienced death or disease progression before WGTA data were acted on and, thus, did not have repeated outcomes data available for DID.

2.2 Data sources and derived variables

BC Cancer’s linked administrative datasets captured POG enrollment, demographics, clinical characteristics, all treatment history, including therapies administered off-label or in clinical trials, and real-world endpoints, including TTD, TTNT, and treatment costs. We measured treatment costs from a real-world cancer care system perspective. BC Cancer Pharmacy data capture costs for all approved systemic therapy drugs administered in regional cancer centers, community hospitals, or taken at home, as well as costs for drugs dispensed concurrently to prevent or manage toxicity. Costs for non-approved systemic therapy drugs, including those administered in clinical trials, were imputed by multiplying list prices reported in Table S1 with either observed dosage or average dosage from cited data source, over the observed treatment period. Costs are reported in 2018 Canadian dollars. Sensitivity analysis considered drug prices as an additional outcome rather than costs over the treatment duration (reported in Supplementary Materials). We calculated patients’ TTD as the duration from treatment initiation to discontinuation due to progression, toxicity, patient preference, or death. TTNT measured duration from treatment initiation to start of next treatment or death.

FIGURE 1 Study flow diagram
2.3 Statistical analysis

Baseline differences were characterized across treatment groups using logistic regression of the probability of genomics-informed treatment. The regression considered patient characteristics hypothesized to correlate with availability of and access to targeted treatments, including: age, sex, geographic area classification, primary cancer type, stage at diagnosis, and number of lines of prior systemic therapy. We selected our final model to maximize model goodness of fit as indicated by Akaike information criteria.\(^1\)\(^8\)

DID estimated the effects of genomics-informed care versus standard care on TTD, TTNT, and treatment costs. In stratified models, we assessed effect modification for the two most common primary cancer types observed within cohort. To account for censoring due to incomplete follow up, DID regressions were weighted by each individual’s inverse probability of censoring. Weights were based on product limit estimates of probability of censoring over the study period. Non-parametric bootstrapping clustered by primary tumor site estimated standard errors. Reported confidence intervals are bias corrected.\(^1\)\(^9\) We conducted all analyses in Stata 15 (StataCorp). To identify statistical significance, we applied a threshold of \(p < 0.05\), adjusted for multiple comparisons using a Bonferroni correction.\(^2\)\(^0\) Our study was approved by the UBC-BC Cancer Research Ethics Board (Certificate No. H18-00767).

3 RESULTS

From July 2012 to December 2017, 346 patients with advanced cancer were enrolled in the BC POG program and met our study criteria. Of these, 140 (40\%) received a genomics-informed treatment and 206 (60\%) received standard care treatment after sequencing. A detailed list of all genomics-informed treatments received during the period is provided in Table S2. WGTA-informed treatments were accessed through clinical trials (4\%), through off-label or experimental use of drugs either restricted in funding or not publicly funded (38\%), and as standard therapies (58\%). Common reasons for not providing WGTA-informed treatments included ongoing response to standard care treatment (\(n = 84, 42\%\)), no clinically actionable findings generated through WGTA (\(n = 45, 23\%\)), no targeted therapies available or accessible to patients (\(n = 23, 12\%\)), and death or disease progression (\(n = 6, 3\%\)).

Table 1 describes the study characteristics for our cohort. After adjusting for multiple comparisons, there were no significant baseline differences across groups. Most patients lived in urban areas (\(n_{\text{standard}} = 161, 78\%\) and \(n_{\text{genomics}} = 106, 76\%\), and were diagnosed with breast cancers (\(n_{\text{standard}} = 75, 36\%\), \(n_{\text{genomics}} = 42, 30\%\)) or gastrointestinal cancers (\(n_{\text{standard}} = 41, 20\%, n_{\text{genomics}} = 30, 21\%\)), most often colorectal. On average, participants were aged 55 (\(SD_{\text{standard}} = 12.24\) and \(SD_{\text{genomics}} = 13.58\)), diagnosed with cancer in 2011 (\(SD_{\text{standard}} = 5.81\)) or 2010 (\(SD_{\text{genomics}} = 7.77\)), and received 2.6 (\(SD_{\text{standard}} = 1.66\)) or 2.7 lines (\(SD_{\text{genomics}} = 1.74\)) of systemic therapy prior to WGTA. Logistic regression results (Table S3) indicated the probability of receiving WGTA-informed treatment was not jointly influenced by included covariates (\(p = 0.52\)).

POG enrollment was ongoing throughout the period and follow-up times ranged from 1.12 years to 6.38 years. Median follow-up was 2.83 years in genomics-informed patients and 2.59 years in standard care patients. Incomplete follow up resulted in 6\% of patients having censored TTD and treatment costs and 13\% having censored TTNT in period 2. While the majority of treatment costs were reimbursed by BC’s public single-payer system, 15\% (\(n = 21\)) of patients receiving genomics-informed treatment paid out of pocket.

3.1 Pooled analysis

Trends in time-varying outcomes are depicted in Figure 2. DID regression is reported in Table 2. Average TTD was significantly shorter in period 1 in genomics-informed patients compared to standard care patients (mean difference: \(\Delta x_{\text{TTD,pre}} = −94\) days, 95\% CI: −143, −45). TTNT was shorter and treatment costs were lower but not significant (\(\Delta x_{\text{TTNT,pre}} = −89, 95\%\) CI: −174, 5 and \(\Delta x_{\text{cost,pre}} = −$33,354, 95\%\) CI: −$61,609, −$12,365). Pre-sequencing clinical outcomes were thus, poorer for patients who received WTGA-informed treatment compared to those continuing with standard care, suggesting baseline differences in responsiveness to standard care therapies or phase of treatment.

Downward time trends in average TTD and TTNT were observed irrespective of treatment group (\(\Delta x_{\text{TTD,standard}} = −132\) days, 95\% CI: −179, −93, \(\Delta x_{\text{TTD,genomics}} = −30\) days, 95\% CI: −78, 26, \(\Delta x_{\text{TTNT,standard}} = −224\) days, 95\% CI: −296, −168, and \(\Delta x_{\text{TTNT,genomics}} = −133\) days, 95\% CI: −216, −79), whereas trends in treatment costs were opposite across groups (\(\Delta x_{\text{cost,standard}} = −$34,958, 95\%\) CI: −$64,344, −$13,729; \(\Delta x_{\text{costs,genomics}} = $56,140, 95\%\) CI: $15,490, $136,701). Trends are indicative of increasingly shorter response times on subsequent lines of therapy as treatment resistance develops.

Accounting for baseline differences and observed time trends, DID estimated that genomics-informed versus standard care treatment had a statistically significant incremental effect of 102 days (95\% CI: 35, 167) on TTD at a statistically significant incremental effect of $91,098 per patient (95\% CI: $46,848, $176,598). Sensitivity analysis reported in Table S4 revealed no significant differences in drug prices across groups, demonstrating that higher treatment costs primarily resulted from extended durations of use. Although TTNT was higher after genomics-informed treatment, this
difference was not significant (91 days, 95% CI: −9, 175), with estimates suggesting less durable response and lower efficacy for standard care.

### 3.2 Stratified analysis

Stratifying our analysis according to the two most common cancer types revealed outcomes heterogeneity that was masked in the pooled results. Table S5 presents stratified regressions for breast, gastrointestinal, and other cancers.

### 3.3 Breast cancer (n = 117)

Similar to pooled analysis, we found that period 1 treatment costs for breast cancer were significantly lower among genomics-informed patients ($\Delta\bar{x}_{\text{cost,pre}}$ $-16,981$, 95% CI: $-29,412$, $-7,753$) compared to usual care. We also found downward trends in TTNT over time among genomics-informed and usual care patients ($\Delta\bar{x}_{\text{TTNT,standard}} = -210$ days, 95% CI: $-347$, $-122$, and $\Delta\bar{x}_{\text{TTNT,genomics}} = -126$ days, 95% CI: $-218$, $-43$) and downward trends in TTD and treatment costs among usual care patients ($\Delta\bar{x}_{\text{TTD,standard}} = -72$ days, 95% CI: $-128$, $-11$ and $\Delta\bar{x}_{\text{cost,standard}} = -16,976$, 95% CI: $-29,989$, $-8135$).

Key differences among breast cancer patients were that no significant baseline differences in TTD or TTNT were present across patient groups and no significant trends in TTD or treatment costs were observed in genomics-informed patients. Within breast cancers, WGTA-informed treatment did not have a statistically significant incremental effect on TTD, TTNT, or treatment costs compared to standard care.
Stratified results for patients with gastrointestinal cancers were largely consistent with pooled results. Significantly lower baseline outcomes were present in genomics-informed versus usual care patients ($\Delta x_{\text{TTD, pre}} = -295, 95\% \text{ CI: } -500, -169$; $\Delta x_{\text{TTNT, pre}} = 312, 95\% \text{ CI: } -551, -194$; $\Delta x_{\text{cost, pre}} = -31,230, 95\% \text{ CI: } -$46,896, $-19,659$) and downward trends in TTD, TTNT, and treatment costs were detected among usual care patients ($\Delta x_{\text{TTD, standard}} = -298 \text{ days}, 95\% \text{ CI: } -512, -171$; $\Delta x_{\text{TTNT, standard}} = -370 \text{ days}, 95\% \text{ CI: } -632, -279$; and $\Delta x_{\text{cost, standard}} = -$23,375, 95\% CI: $-38,301, -$7471). For gastrointestinal cancers, patients who received WGTA-informed treatment had significantly higher TTD, TTNT, and treatment cost compared to standard care. Incremental effects ranged from 284 days (95\% CI: 138, 525) on TTD to 327 days (95\% CI: 202, 623) on TTNT to $53,861 (95\% \text{ CI: }$16,250, $126,342) on treatment costs.

### 3.5 Other cancers (n = 158)

Among patients diagnosed with other cancers, estimated magnitudes and directions often aligned with pooled results, although few differences remained significant after correcting for multiple comparisons ($p > 0.006$). In period 1,
WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.

WEYMANN ET AL.
Prior to sequencing, standard care patients had significantly higher TTD and treatment costs compared to patients receiving WGTA-informed treatment, despite having similar enrollment characteristics. While unadjusted analyses across these patient groups would result in biased effect estimates, baseline outcomes differences do not directly threaten the validity of DID estimates.27 Observed differences do suggest possible variation in either responsiveness to previous standard care therapies or treatment phase. Sensitivity analysis excluding patients who did not receive genomics-informed treatment because of ongoing response to standard care \( n = 48 \) did not substantively change effect estimates (Table S6). Furthermore, potential non-constant trends in outcomes across treatment phases are most likely to underestimate true effects of genomics-informed care owing to established patterns of acquired treatment resistance.28

To our knowledge, ours is the first study to estimate the comparative effectiveness of genomics-informed versus standard care treatment and the first to consider DID for evaluating single-arm precision oncology initiatives. The DID approach is common in health research and is well suited to within-cohort estimation of causal time-varying treatment effects.29–33 For determining efficacy and effectiveness, this method necessitates patient-level outcomes data amenable to repeated measurement. Although survival is observed only once at an individual level and is not suitable for DID, time-varying patients endpoints are commonly used to characterize early-stage impacts of cancer therapies while long-term evidence is being generated.34,35 While real-world time-varying endpoints measured in this study correlate with common efficacy endpoints for certain advanced cancers, including treatment response, progression, and survival, their performance in a tumor-agnostic population is not yet established.12–14

Owing to our study’s small sample size, subgroup analysis was only possible in select cancer subtypes. Future research powered to detect differences across all cancers is necessary to guide decision-making. Treatment costs were also estimated using list prices where internal estimates were unavailable, which may overestimate actual expenditures. DID requires repeated outcomes data and POG patients who did not initiate a new treatment after WGTA, either owing to ongoing treatment response or death or disease progression, were not eligible for this study, affecting the cohort composition and generalizability of our study findings. Causality of our results also relies on the parallel trends assumption underlying DID analysis, which cannot be tested for in a two-period setting. While early-stage analyses of short-term outcomes are least likely to be severely impacted by deviations from this assumption, there is an unmet need for quasi-experimental methods development robust to time-varying confounding.

5 CONCLUSIONS

In the continued absence of RCTs, DID is a tool to address confounding bias for precision oncology. By expanding the application of DID methods to evaluate single-arm trial data, we find that genomics-informed treatment has a statistically significant effect on TTD and treatment costs compared to standard care treatment in patients with advanced cancers. Our study will guide future quasi-experimental within-cohort evaluations enabling early-stage estimation of precision oncology’s clinical and economic impacts. Broadening the spectrum of evidence generated throughout the technology life cycle will provide critical support for reimbursement decision-making.

ACKNOWLEDGMENTS

We gratefully acknowledge the participation of our patients and families, the POG team, the GSC platform, and the generous support of the BC Cancer Foundation and Genome British Columbia (project B20POG). We also acknowledge contributions toward equipment and infrastructure from Canada Foundation for Innovation (projects 20070, 30981, 30198, 33408, and 35444) and the BC Knowledge Development Fund. The results published here are in part based upon data generated by the following projects and obtained from dbGaP (http://www.ncbi.nlm.nih.gov/gap): The Cancer Genome Atlas managed by the NCI and NHGRI (http://cancer.gov) and Genotype-Tissue Expression (GTEx) Project supported by the Common Fund of the Office of the Director of the National Institutes of Health (https://commonfund.nih.gov/GTEx).

CONFLICT OF INTEREST

Brandon Chan, Steven J.M. Jones, and Marco A. Marra report no conflicts of interest. Deirdre Weymann and Samantha Pollard codirect IMPRINT Research Consulting and have consulted for Roche Canada. Janessa Laskin has received honoraria for academic talks from: Roche Canada, Pfizer Canada, Astra-Zeneca Canada, and BI Canada; her institution has received research funding for her projects from: Roche Canada, Asta-Zeneca Canada and BI Canada. Daniel J. Renouf disclosures include research funding and honoraria from Bayer and Roche, and travel funding and honoraria from Servier, Celgene, Taiho, Ipsen, and Astra Zenec. Howard Lim has received honoraria from Eisai, Taiho, Roche, Lilly, BMS, Amgen, and Leo for consultant work and is an investigator on trials with Bayer, BMS, Lilly, Roche, Astra-Zeneca, and Amgen. Sophie Sun has received research grant and honoraria funding from Astra-Zeneca. Stephen Yip is an advisory board member for and has received travel allowance from Amgen, AstraZeneca, Bayer, Norvatis, and Roche. Dean A. Regier has received speaking honoraria from Roche Canada. DF Schaeffer has received honoraria from Alimentiv, Pfizer,
Merck, and Diaceutics. Kasmintan A. Schrader has received speaking honoraria from AstraZeneca and Pfizer.

AUTHOR CONTRIBUTIONS
Study conception and design: All authors. Statistical analysis: DW, BC, and DAR. Drafting of the manuscript and final approval: All authors. Guarantor of work: DW and DAR.

DATA AVAILABILITY STATEMENT
Patient-level administrative data used in this retrospective study are confidential and are not available in a public repository, in accordance with institutional policies.

ORCID
Deirdre Weymann https://orcid.org/0000-0002-3072-5657

REFERENCES
1. Roberts MC, Kennedy AE, Chambers DA, Khoury MJ. The current state of implementation science in genomic medicine: opportunities for improvement. Genet Med. 2017;19:858–863.
2. Rogowski W, Payne K, Schnell-Indest P, et al. Concepts of ‘personalization’ in personalized medicine: implications for economic evaluation. Pharmacoeconomics. 2015;33:49–59.
3. Weymann D, Pataky R, Regier DA. Economic evaluations of next-generation precision oncology: a critical review. JCO Precis Oncol. 2018;2:1–23.
4. Le Tourneau C, Delord J-P, Gonçalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16:1324–1334.
5. Tsimberidou AM, Kurzrock R. Precision medicine: lessons learned from the SHIVA trial. Lancet Oncol. 2015;16:e579–e580.
6. Soldatos TG, Kaduthanam S, Jackson DB. Precision oncology—the quest for evidence. J Pers Med. 2019;9:43.
7. Presley CJ, Tang D, Soulouros PR, et al. Association of broad-based genomic sequencing with survival among patients with advanced non-small cell lung cancer in the community oncology setting. JAMA. 2018;320:469–477.
8. Weymann D, Laskin J, Jones SJM, et al. Matching methods in precision oncology: an introduction and illustrative example. Mol Genet Genomic Med. 2020;9:e1554.
9. Dimick JB, Ryan AM. Methods for evaluating changes in healthcare policy: the difference-in-differences approach. JAMA. 2014;312:2401–2402.
10. Laskin J, Jones S, Aparicio S, et al. Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. Mol Case Stud. 2015;1:e000570.
11. Pleasance E, Titmuss E, Williamson L, et al. Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes. Nature Cancer. 2020;1:452–468.
12. Savina M, Le Cesne A, Blay J-Y, et al. Patterns of care and outcomes of patients with METastatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med. 2017;15:78.
13. Gong Y, Kehl KL, Oxnard GR, et al. Time to treatment discontinuation (TTD) as a pragmatic endpoint in metastatic non-small cell lung cancer (mNSCLC): a pooled analysis of 8 trials. J Clin Oncol. 2018;36:9064.
14. Blumenthal G, Gong Y, Kehl K, et al. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. Annals of Oncology. 2019;30:830–838.
15. Oxnard GR, Morris MJ, Hodi FS, et al. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst. 2012;104:1534–1541.
16. Shoushtari AN, Friedman CF, Navid-Azarbaijani P, et al. Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma. JAMA Oncol. 2018;4:98–101.
17. Oxnard GR, Hu Y, Mileham KF, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 2018;4:1527–1534.
18. Akaike H. Information theory and an extension of the maximum likelihood principle. In: Parzen E, Tanabe K, Kitagawa G eds. Selected papers of Hirotugu Akaike. Springer Series in Statistics (Perspectives in Statistics). 1st ed. New York, NY: Springer; 1998:199–213.
19. Efron B. Better bootstrap confidence intervals. J Am Stat Assoc. 1987;82:171–185.
20. Dunn OJ. Multiple comparisons among means. J Am Stat Assoc. 1961;56:52–64.
21. Von Hoff DD, Stephenson JJ, Rosen P, et al. Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010;28:4877–4883.
22. Tuxen IV, Rohrberg KS, Oestrup O, et al. Copenhagen prospective personalized oncology (COPPO)—clinical utility of using molecular profiling to select patients to phase I trials. Clin Cancer Res. 2019;25:1239–1247.
23. Cressman S, Brownman GP, Hoch JS, Kovacic L, Peacock SJ. A time-trend economic analysis of cancer drug trials. Oncologist. 2015;20:729–736.
24. Murphy P, Claxton L, Hodgson R, et al. Exploring heterogeneity in histology-independent technologies and the implications for cost-effectiveness. Med Decis Making. 2021;41(2):165–178.
25. Yabroff KR, Zhao J, de Moor JS, et al. Factors associated with differences in differences analysis. Health Serv Res. 2018;53:4138–4156.
26. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219–234.
27. Ryan AM, Burgess JF Jr, Dimick JB. Why we should not be indifferent to specification choices for difference-in-differences. Health Serv Res. 2015;50:1211–1235.
28. Albright BB, Nasiroudis D, Craig S, et al. Impact of Medicaid expansion on women with gynecologic cancer: a difference-in-difference analysis. Am J Obstetrics Gynecol. 2021;224(2):195.e1–195.e17.
29. Fu AZ, Dow WH, Liu GG. Propensity score and difference-in-difference methods: a study of second-generation antidepressant
use in patients with bipolar disorder. *Health Serv Outcomes Res Methodol.* 2007;7:23–38.

32. Dalsgaard S, Leckman JF, Mortensen PB, Nielsen HS, Simonsen M. Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. *Lancet Psychiatry.* 2015;2:702–709.

33. Öhman M, Woodford J, von Essen L. Socioeconomic consequences of parenting a child with cancer for fathers and mothers in Sweden: A population-based difference-in-difference study. *Int J Cancer.* 2021;148:2535–2541.

34. Shi Q, Sargent DJ. Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. *Int J Clin Oncol.* 2009;14:102–111.

35. Kay A, Higgins J, Day A, Meyer R, Booth C. Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points. *Ann Oncol.* 2012;23:1646–1651.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Weymann D, Pollard S, Chan B, et al. Clinical and cost outcomes following genomics-informed treatment for advanced cancers. *Cancer Med.* 2021;00:1–10. [https://doi.org/10.1002/cam4.4076](https://doi.org/10.1002/cam4.4076)